A Phase 1 interventional study of D-0502 in Healthy Female Volunteer, sponsored by InventisBio Co., Ltd. Completed at 1 site in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-08.
Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Relative Bioavailability study of D-0502 tablet formulation in healthy female subjects
Phase 1, Open Label, Randomized, Single dose, 3 Period, 3 treatment study to evaluation the relative Bioavailability of D-0502 tablet formulation in healthy female subjects
InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
3 period, 3 dose level
Drug: D-0502
3 period, 3 dose level
Drug: D-0502
3 period, 3 dose level
Drug: D-0502
3 period, 3 dose level
Drug: D-0502
3 period, 3 dose level
Drug: D-0502
3 period, 3 dose level
Drug: D-0502
Formulation 1 Formulation 2 Formulation 3
Access the oral bioavailability of D-0502 100mg and 200mg tablets
Access the oral bioavailability of D-0502 100mg and 200mg tablets relative to D-0502 50mg tablet formulation
Time frame: Single Dose, 3 period, 3 treatment study separated by 14 day washout periods to evaluate safety and bioavailability. Overall time in study is approximately 42 days.
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2021 to primary completion in Dec 2021, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Taragarestrant